S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development
Send us a text 00:00:00 - Surf's Up: Season 6 Episode 7 Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activity and the increasing role of NITs in drug development. While introducing roundtable guests, he introduces first-time Surfer Dr. Kristina Curtis o...
17 Juli 1h 9min
S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH
Send us a text 00:00:00 Surf's Up, Season 6, Episode 6. On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Development, Part 2 The second portion of the Drug Development roundtable primarily focuses on three key issues. The first, uptake of resmetirom...
26 Apr 57min
S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom
Send us a text This weekend’s Newsmaker, Indiana University hepatologist and key opinion leader Naga Chalasani, joins Roger Green to discuss Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting, an article his group published recently in Hepatology Communications. He shares highlights from the paper and points out the one key area in which his group found room for improvement in their initial protocol. Naga and colleagues w...
24 Apr 26min
S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science
Send us a text This week’s expert, Hepatologist and Key Opinion Leader Scott Friedman, joins Roger to discuss advances in acceptance of gene therapy and knowledge in other areas of basic liver science. When discussing science, he pays particular attention to findings on the diversity of stellate cells and his interest in CAR-T as a therapy for liver disease. This conversation starts with Scott discussing gene therapy. Specifically, he applauds the idea that gene therapy is becoming acce...
24 Apr 23min
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis
Send us a text This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exciting advances in one drug class (FGF-21s) and, more broadly, on exploring ways to treat cirrhosis. As Naim points out in his opening comment,...
22 Apr 24min
S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies
Send us a text 00:00:00 - Surf's Up: Season 6 Episode 5 Host Roger Green briefly describes this episode’s three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part One The opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by fo...
18 Apr 1h 9min
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment
Send us a text This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He poin...
13 Apr 24min
S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates
Send us a text This weekend's Newsmaker, Fatty Liver Alliance Founder Mike Betel, joins Roger Green to discuss the wide range of conferences where he has been invited to speak or sit on a panel this year. Specifically, he shares his belief on what this says about interest in MASLD and describes the messages he delivers at the conferences he attends. The interview starts with Roger asking about the benefits societies and the broader community get from having Mike at these programs. As he...
12 Apr 31min
